The B7-1/B7-2–CD28/CTLA-4 co-stimulatory pathway has a crucial role in regulating T-cell activation and tolerance. New B7 and CD28 family members and new pathways have recently been identified that ...

Regeneron is rethinking development of its prostate cancer bispecific after two patients died in a clinical trial. The deaths prompted the Big Biotech to stop enrolling patients to receive REGN5678 ...

The numbers of T-cell receptors (TCRs) engaged, as well as the time of interaction with the major histocompatibility complex (MHC)–peptide complexes, determine whether T-cell activation occurs.

ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic ...

-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 ...

Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly ...

Improving risk stratification among veterans with newly diagnosed, clinically low-risk prostate cancer using the 17-gene genomic prostate score assay. This is an ASCO Meeting Abstract from the 2016 ...

Alpine Immune Sciences turned heads a year ago when AbbVie formed a deal with the company worth up to $805 million in milestone payments for a first-in-class lupus drug that inhibits a protein on the ...

HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for ...

Bispecific T cell engagers (BiTEs) are engineered proteins combining the variable regions isolated from two different antibodies. By binding to both T cells and cancer cells, BiTEs help endogenous T ...